Matica Biotechnology, a Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has entered a strategic partnership with Mongoose Bio focused on the full development and production of lentivirus for Mongoose Bio’s T cell receptor-engineered T cell (TCR-T) pipeline for cancer treatment.
 
Under the terms of the agreement, Matica Bio will provide comprehensive services, including process development, analytical method development, and the manufacturing of non-clinical and clinical materials of the viral vector. The produced lentivirus vector will be used as an intermediate product in the manufacturing of the final TCR-T cell therapy.
 
“We are pleased to be working with Matica Bio on viral vector manufacturing to advance our novel TCR-T therapies into the clinic,” said Neil Warma, President and CEO of Mongoose Bio. “Our novel technology is based on over 20 years of research and development expertise and an extensive patent portfolio. It is particularly meaningful to collaborate with leading CDMOs, like Matica Bio, hospitals, and development companies in our goal of conducting global clinical trials to bring our cancer treatments to patients worldwide.”
 
“We are honored to collaborate with a team that shares our dedication to improving patient outcomes and advancing the frontiers of cancer treatment,” added Paul Kim, CEO of Matica Bio.